Form 4: Arcadia Biosciences CEO Thomas J. Schaefer Reports Stock Option Grant

Arcadia Biosciences CEO Thomas J. Schaefer reports the acquisition of stock options.

Summary

• Thomas J. Schaefer, CEO of Arcadia Biosciences, reported a transaction on May 9, 2025.
• Schaefer acquired 12,500 stock options with an exercise price of $3.88.
• These options vest over time, with 25% vesting on the first anniversary of the grant date and the remaining 75% vesting in 36 equal monthly installments.
• Following the reported transaction, Schaefer directly owns 37,975 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants, which is neither particularly positive nor negative on its own.

Positives

• The granting of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to increase the company's value.

Industry Context

This is a standard practice for publicly traded companies to incentivize their executives.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in publicly traded companies, particularly in growth-oriented sectors like biotechnology and agriculture.
• The vesting schedule described (25% after one year, then monthly) is a fairly standard vesting arrangement.
• Comparing the size of the grant (12,500 options) to grants at comparable companies would require more data on Arcadia's market cap and executive compensation policies.

Stakeholder Impact

• The stock option grant aligns the CEO's interests with shareholders, potentially benefiting them if the company performs well.

Key Dates

Keywords

stock options, Form 4, Arcadia Biosciences, RKDA, CEO, Thomas J. Schaefer, insider trading, beneficial ownership